GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Surface Oncology Inc (NAS:SURF) » Definitions » Cash Flow from Investing

Surface Oncology (Surface Oncology) Cash Flow from Investing : $41.35 Mil (TTM As of Jun. 2023)


View and export this data going back to 2018. Start your Free Trial

What is Surface Oncology Cash Flow from Investing?

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

For the three months ended in Jun. 2023, Surface Oncology spent $-0.02 Mil on purchasing property, plant, equipment. It gained $-0.03 Mil from selling property, plant, and equipment. It spent $0.00 Mil on purchasing business. It gained $0.00 Mil from selling business. It spent $18.64 Mil on purchasing investments. It gained $50.72 Mil from selling investments. It paid $0.00Mil for net Intangibles purchase and sale. And it paid $0.00 Mil for other investing activities. In all, Surface Oncology gained $32.07 Mil on investment activities in financial market and operating subsidiaries for the three months ended in Jun. 2023.


Surface Oncology Cash Flow from Investing Historical Data

The historical data trend for Surface Oncology's Cash Flow from Investing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Surface Oncology Cash Flow from Investing Chart

Surface Oncology Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Cash Flow from Investing
Get a 7-Day Free Trial -36.58 16.97 58.31 -99.25 22.76

Surface Oncology Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
Cash Flow from Investing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.44 0.32 7.53 1.43 32.07

Surface Oncology Cash Flow from Investing Calculation

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

If a company spends cash on property, plant and equipment (PPE), this will reduce their cash position. This is called Capital Expenditures (CPEX).

Likewise, if a company buys another company for cash, this will reduce their cash position.

Surface Oncology's Cash Flow from Investing for the fiscal year that ended in Dec. 2022 is calculated as:

Surface Oncology's Cash Flow from Investing for the quarter that ended in Jun. 2023 is calculated as:


Cash Flow from Investing for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $41.35 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Surface Oncology  (NAS:SURF) Cash Flow from Investing Explanation

Cash flow from investing contains nine items:

1. Purchase Of Property, Plant, Equipment:
Purchase of PPE indicates the amount used to purchase property, plant, and equipment.

Surface Oncology's purchase of property, plant, equipment for the three months ended in Jun. 2023 was $0.02 Mil. It means Surface Oncology spent $-0.02 Mil on purchasing property, plant, equipment.

In the capital spending for property, plant and equipment (PPE), some part of spending may be from the expansion of business. The business needs more property, plant and equipment (PPE) as it grows. Another part may be from replacement of the property, plant and equipment (PPE) of existing business. For some companies, the cash spent on replacing of the property, plant and equipment (PPE) of the existing business will be close to the depreciation of property, plant and equipment (PPE) reported in the income statement.

In Warren Buffett's definition of Owner's Earnings, he deducts the estimate of the cost of replacing the property, plant and equipment (PPE) of the existing business from cash flow from operations. The cash spent on the new property, plant, and equipment is not deducted. The reason is because these are not costs of the existing business. In his 1986 letter to shareholders, Warren Buffett wrote this about owner earnings:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume....Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

2. Sale Of Property, Plant, Equipment:
Sale of PPE indicates the amount gained from selling property, plant, and equipment.

Surface Oncology's sale of property, plant, equipment for the three months ended in Jun. 2023 was $-0.03 Mil. It means Surface Oncology gained $-0.03 Mil from selling property, plant, and equipment.

3.Purchase Of Business:
Purchase of business indicates the amount used to purchase business.

Surface Oncology's purchase of business for the three months ended in Jun. 2023 was $0.00 Mil. It means Surface Oncology spent $0.00 Mil on purchasing business.

4. Sale Of Business:
Sale of business indicates the amount gained from selling business.

Surface Oncology's sale of business for the three months ended in Jun. 2023 was $0.00 Mil. It means Surface Oncology gained $0.00 Mil from selling business.

5. Purchase Of Investment:
Purchase of Investments represents cash outflow on the purchase of investments in securities.

Surface Oncology's purchase of investment for the three months ended in Jun. 2023 was $-18.64 Mil. It means Surface Oncology spent {stock_data.stock.currency_symbol}}18.64 Mil on purchasing investments.

6. Sale Of Investment:
Sale of Investments represents cash inflow on the sale of investments in securities.

Surface Oncology's sale of investment for the three months ended in Jun. 2023 was $50.72 Mil. It means Surface Oncology gained $50.72 Mil from selling investments.

7. Net Intangibles Purchase And Sale:
Net Intangibles purchase and sale means the net cash inflow received by a company that comes from the purchase and sale of intangibles. It equals the cash received from sale of intangibles minus the cash spent on purchasing intangibles.

Surface Oncology's net Intangibles purchase and sale for the three months ended in Jun. 2023 was $0.00 Mil. It means Surface Oncology paid $0.00 Mil for net Intangibles purchase and sale.

8. Cash From Discontinued Investing Activities:
Cash from discontinued investing activities means the cash received by a company that comes from the discontinued investing activities.

Surface Oncology's cash from discontinued investing activities for the three months ended in Jun. 2023 was 0.00 Mil. It means Surface Oncology paid $0.00 Mil for discontinued investing activities.

9. Cash From Other Investing Activities:
Cash from other investing activities means the cash received by a company that comes from other investing activities.

Surface Oncology's cash from other investing activities for the three months ended in Jun. 2023 was $0.00 Mil. It means Surface Oncology paid $0.00 Mil for other investing activities.


Surface Oncology Cash Flow from Investing Related Terms

Thank you for viewing the detailed overview of Surface Oncology's Cash Flow from Investing provided by GuruFocus.com. Please click on the following links to see related term pages.


Surface Oncology (Surface Oncology) Business Description

Traded in Other Exchanges
N/A
Address
50 Hampshire Street, 8th Floor, Cambridge, MA, USA, 02139
Surface Oncology Inc is a clinical-stage immuno-oncology company. It is developing new therapies that modify the spaces in and around tumors in the tumor microenvironment to create conditions that support and sustain anti-tumor immune responses. The company's pipeline products are SRF231, SRF373, SRF617, and SRF388. Geographically, the activities are carried out throughout the region of the United States.
Executives
Chandra Adams officer: Deputy GC SURFACE ONCOLOGY, INC., 50 HAMPSHIRE STREET, 8TH FLOOR, CAMBRIDGE MA 02139
Alison Oneill officer: Chief Medical Officer
Jessica Fees officer: See Remarks C/O SURFACE ONCOLOGY, ICN., 50 HAMPSHIRE STREET 8TH FLOOR, CAMBRIDGE MA 02139
Robert W. Ross officer: Chief Medical Officer C/O SURFACE ONCOLOGY, 50 HAMPSHIRE ST., 8TH FLOOR, CAMBRIDGE MA 02139
Henry C. Rath officer: Chief Business Officer C/O SURFACE ONCOLOGY, INC., 50 HAMPSHIRE STREET 8TH FL, CAMBRIDGE MA 02139
Vito J. Palombella officer: Chief Scientific Officer 780 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Carsten Brunn director C/O SELECTA BIOSCIENCES, INC., 480 ARSENAL WAY, WATERTOWN MA 02472
Theresa Boni officer: General Counsel C/O SURFACE ONCOLOGY, INC., 50 HAMPSHIRE STREET, 8TH FLOOR, CAMBRIDGE MA 02139
Benjamin Hickey director C/O MIRATI THERAPEUTICS, 9393 TOWNE CENTRE DRIVE SUITE 200, SAN DIEGO CA 92121
Liisa I Nogelo officer: General Counsel C/O SURFACE ONCOLOGY, INC., 50 HAMPSHIRE STREET 8TH FLOOR, CAMBRIDGE MA 02139
Jeff Goater director, officer: Chief Executive Officer C/O SURFACE ONCOLOGY, INC., 50 HAMPSHIRE STREET, 8TH FLOOR, CAMBRIDGE MA 02139
Denice Torres director 3 RABBIT RUN DRIVE, NEW HOPE PA 18938
David S. Grayzel director C/O SURFACE ONCOLOGY, 50 HAMPSHIRE ST., 8TH FLOOR, CAMBRIDGE MA 02139
Atlas Venture Associates Ix, L.p. 10 percent owner 46 WAREHAM STREET, FLOOR 3, BOSTON MA 02118
Atlas Venture Associates Ix, Llc 10 percent owner 56 WAREHAM STREET, FLOOR 3, BOSTON MA 02118

Surface Oncology (Surface Oncology) Headlines

From GuruFocus